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CASE REPORTSDemonstration of persistent tumor cells 4 weeks after radiofrequency
ablation of a pulmonary adenocarcinomaStephane Renaud, Marco Schiavon, MD, Nicola Santelmo, MD, and Gilbert Massard, MD, PhD,
Strasbourg, FranceRadiofrequency ablation (RFA) has gained steadily in-
creasing interest as an alternative to surgery. Previous re-
ports on primary nonsmall-cell lung cancer (NSCLC)
have shown a local control rate after RFA varying between
58% and 68% (median follow-up between 17 and 28
months), with an overall 3-year survival rate of 47%.1,2
Pneumothorax represents the main complication of RFA,
occurring in 17% to 68% of procedures.1,2 We report
a case of a wedge resection performed 4 weeks after
RFA containing 40% viable adenocarcinoma cells.CLINICAL SUMMARY
A 58-year-old patient with stage 3 smoking-induced
chronic obstructive pulmonary disease (forced expiratory
volume at 1 second at 43% of predicted), presented with
a nodular adenocarcinoma of the left upper lobe measur-
ing 15 mm (Figure 1, A). Staging, including brain and
abdominal computed tomography (CT) scan failed to
identify metastases. Because of ischemic heart disease
with left ventricular ejection fraction at 50%, the patient
was deemed unfit for surgery without discussion at
the multidisciplinary board, and was offered percutane-
ous RFA.
An expandable monopolar needle 4 cm in diameter was
inserted using CT guidance (Figure 1, B). The session
lasted 7 minutes with a wattage-current setting of 40 W.
CT scan after the procedure showed a successful ablation,
characterized by a peritumoral ground glass opacity, and
obviated a pneumothorax requiring drainage (Figure 1,
C). The patient was referred to us for surgical revision
4 weeks later because of a major persisting air leak. Explo-
ration of the pleural cavity disclosed a necrotic lesion in
the left upper lobe measuring 5 cm, centered by a 3-mm
pin-shaped hole with escaping air (Figure 2, A). Lobec-
tomy was considered to present a high risk for vascular in-
jury because of the fragility of the tissues, hilar
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eventful; chest tubes were withdrawn on Postoperative
Day 4, and the patient was discharged on Postoperative
Day 6.
Pathologic examination after tissue fixation and staining
of slides with hematoxylin-eosin showed evidence of per-
sistence of 40% viable adenocarcinoma cells with pre-
served cytoplasm, nuclei, and mitotic figures, located both
close and at distance of vessels (Figure 2, B and C). To as-
sess the proliferative potential, an immunohistochemical
analysis was performed with anti-Ki67 antibodies (clone
SP6, Neomarkers; Thermo Scientific Pierce Products,
Rockford, Ill), which revealed nuclear marking of a vast
majority of these cells (Figure 2, D).DISCUSSION
RFA is a procedure in which high-frequency electrical
currents are delivered through an electrode, creating
heat that coagulates surrounding tissues. Close vicinity
of the tumor to blood vessels is an important limitation
factor, because heat may be dissipated by blood flow.3
This ‘‘heat sink effect’’ might explain inefficiency in
our case.
Data regarding efficacy of RFA are limited. Most avail-
able reports pool primary and metastatic tumors with
a short-term follow-up. In our case, histologic analysis
was achieved 4 weeks after RFA, revealing persistence of
40% of viable cells, of which a vast majority still showed
proliferative potential, signed by Ki67 immunostaining.
Unfortunately, we have no histologic documentation of
the immediate postintervention status. We only can hypoth-
esize that either the initial destruction concerned only 60%,
or that there was a proliferation from a smaller population of
persistent viable cells. Our case suggests that persistence
of viable cells may evolve to proliferation with tumor
growth and metastatic spread. Furthermore, Schneider and
colleagues3 reported that effectiveness of RFAmay be mod-
ulated by the histologic subtype. He noted that all incom-
plete ablations concerned adenocarcinoma. Our case adds
to this observation.
The main nonsurgical alternative to RFA is stereotac-
tic radiotherapy (SR). Published data concerning pri-
mary NSCLC involve larger populations than published
data concerning RFA, and obviate a more satisfactory lo-
cal control rate exceeding 90% at 3 years; 5-year overall
survival rates range up to 78%.4,5 Further, RFA is flawed
by a high incidence of procedure-related pneumothorax,diovascular Surgery c Volume 144, Number 5 e111
FIGURE 1. Computed tomography scans taken before, during, and after the treatment. A, Supine chest computed tomography scan performed before
radiofrequency treatment showing lesion located in left upper lobe. B, Prone computed tomography scan during radiofrequency treatment with
correct insertion of the probe in the lesion. C, Prone computed tomography scan after procedure showing a successful radiological procedure and
a pneumothorax.
Case Reportswhich occurs in 16% to 68% of procedures.1,2 Although
air leaks usually spontaneously seal, some patients will
require prolonged drainage or paradoxical surgical
management despite initial contraindication. Therefore,
referring to available evidence, SR is preferable to
RFA as local treatment when surgery is deemed
unsuitable.
Mediastinal lymphadenectomy is one of the fundamen-
tals of oncologic resection, both to ascertain completeness
of resection and accuracy of nodal staging. This require-
ment is not met with purely local treatments such as RFA
or SR. We decided against node dissection in this caseFIGURE 2. A, Intraoperative view of the lesion after wedge resection. B and C,
stain confirming the presence of adenocarcinoma with suspected multiple proli
confirming the presence of major foci of viable neoplastic cells (black arrow)
e112 The Journal of Thoracic and Cardiovascular Surbecause of major inflammatory changes in the surrounding
mediastinal area.
CONCLUSIONS
The first treatment option to consider for patients with
marginal functionality with limited disease is a sublobar re-
section combined with lymph node dissection. The second
option is SR, because its medium-term results approach
those obtained with surgery. Finally, disease management
options for any patient with NSCLC should be discussed
by a multidisciplinary board that includes a certified
thoracic surgeon.Pathologic examination of the specimen marked with hematoxylin & eosin
ferating cells. D, Immunohistochemical analysis using anti-Ki67 antibody
representing>40% of the tumor.
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Radiation Oncology Biol Phys. 2005;5:1427-31.The role of methylene blue in serotonin syndrome following cardiac
transplantation: A case report and review of the literatureKendra J. Grubb,MD,a Jamie L.W. Kennedy,MD,b James D. Bergin,MD,b Danja S.Groves,MD, PhD,c and
John A. Kern, MD,a Charlottesville, VaVasoplegic syndrome (VS) is a common complication of
cardiopulmonary bypass, with an incidence reported be-
tween 5% and 25% for all cardiac operations.1,2
Associated with increased morbidity and mortality,2,3 VS
is characterized by severe systemic arterial hypotension
(mean arterial pressure,<50 mm Hg) and low systemic
vascular resistance (<800 dyne/s/cm5).1,3 The syndrome
is particularly troubling in orthotopic heart transplant
recipients as a result of the untoward effects of increased
fluid and vasopressor requirements for resuscitation.
Furthermore, VS is reported to occur in as many as 45%
of patients with a ventricular assist device at the time of
transplantation, making this a particularly high-risk surgical
population.4
The blunting of nitric oxide release has been hypothe-
sized to counter the endothelial dysfunction thought to
cause vasoplegia. Methylene blue interacts with nitric
oxide-mediated pathways via a number of mechanisms, in-
cluding direct nitric oxide binding, inhibition of soluble
guanylate cyclase, and inhibition of nitric oxide syn-
thase.5-7 Methylene blue has been shown to reverse
refractory hypotension associated with vasoplegia.8-10
Furthermore, the benefits of methylene blue for thetreatment of VS have been well documented in cardiac
surgery, and its usage associated with reduced mortality
and morbidity.11,12
In an effort to circumvent the morbidity and mortality as-
sociated with VS, we have implemented successfully an in-
traoperative protocol that includes administration of
methylene blue for VS resistant to vasopressor treatment.
Until now, scant information has been reported about the
untoward effects of methylene blue in the cardiac transplant
patient population. Herein, we describe the first case of
methylene blue-induced serotonin toxicity in a patient after
cardiac transplant. A review of the current literature and
U.S. Federal Drug Administration (FDA) warnings are
included.
CASE REPORT
A 60-year-old male with history of nonischemic cardio-
myopathy and end-stage heart failure underwent placement
of a left ventricular assist device (LVAD) along with re-
placement of a mechanical aortic valve with a porcine pros-
thesis inMarch 2011. His LVAD course was complicated by
multiple driveline infections with Pseudomonas, Serratia,
and, most recently, Achromobacter. He was therefore listed
for heart transplantation as a United Network for Organ
Sharing status 1A. A donor organ became available and
he was brought to the hospital for preoperative management
of anticoagulation and preparation for transplant. Comor-
bidities included insulin-dependent diabetes mellitus, hy-
pertension, obesity status-post gastric bypass surgery,
peptic ulcer disease, chronic kidney disease, gout, and de-
pression, for which he was taking escitalopram 20 mg per
ora daily as well as trazodone 100 mg daily at bedtime.
He underwent a third-time redo sternotomy with femoral
cannulation and initiation of cardiopulmonary bypass. After
the aortic crossclamp was placed, he was noted to havediovascular Surgery c Volume 144, Number 5 e113
